BRPI9908319A - composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo. - Google Patents

composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo.

Info

Publication number
BRPI9908319A
BRPI9908319A BRPI9908319A BRPI9908319A BRPI9908319A BR PI9908319 A BRPI9908319 A BR PI9908319A BR PI9908319 A BRPI9908319 A BR PI9908319A BR PI9908319 A BRPI9908319 A BR PI9908319A BR PI9908319 A BRPI9908319 A BR PI9908319A
Authority
BR
Brazil
Prior art keywords
cyclic amino
amino compound
acceptable salt
pharmacologically acceptable
pharmaceutical composition
Prior art date
Application number
BRPI9908319A
Other languages
English (en)
Inventor
Fumitoshi Asai
Atsuhiro Sugidachi
Toshihiko Ikeda
Haruo Iwabuchi
Yoshiaki Kuroki
Teruhiko Inoue
Ryo Iwamura
Nobuhiko Shibakawa
Original Assignee
Sankyo Co
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co, Ube Industries filed Critical Sankyo Co
Publication of BRPI9908319A publication Critical patent/BRPI9908319A/pt
Publication of BRPI9908319B1 publication Critical patent/BRPI9908319B1/pt
Publication of BRPI9908319B8 publication Critical patent/BRPI9908319B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)

Abstract

"composto amino cíclico, ou sal farmacologicamente aceitável do mesmo, composição farmacêutica, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável". um composto amino cíclico representado pela seguinte fórmula: [em que r¹ representa um grupo fenila substituível, r² represnta um grupo acila alifático substituível, um grupo benzoila substituível ou um grupo alcoxicarbonila, e r³ representa um grupo amino cíclico saturado, substituído, que pode opcionalmente ter um anel fundido] ou um sal farmacologicamente aceitável do mesmo, tem excelente ação inibidora da agregação de plaquetas e é utilizável como um agente preventivo ou remédio para embolismo, trombose ou arteriosclerose.
BRPI9908319 1998-02-27 1999-02-26 composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo. BRPI9908319B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4692198 1998-02-27
PCT/JP1999/000924 WO1999043648A1 (en) 1998-02-27 1999-02-26 Cyclic amino compounds

Publications (3)

Publication Number Publication Date
BRPI9908319A true BRPI9908319A (pt) 2000-11-07
BRPI9908319B1 BRPI9908319B1 (pt) 2012-01-10
BRPI9908319B8 BRPI9908319B8 (pt) 2021-07-06

Family

ID=12760807

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9908319 BRPI9908319B8 (pt) 1998-02-27 1999-02-26 composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo.

Country Status (23)

Country Link
US (1) US6610708B1 (pt)
EP (1) EP1063230B1 (pt)
KR (1) KR100567950B1 (pt)
CN (1) CN100369896C (pt)
AT (1) ATE238279T1 (pt)
AU (1) AU737303B2 (pt)
BR (1) BRPI9908319B8 (pt)
CA (1) CA2322171C (pt)
CZ (1) CZ300821B6 (pt)
DE (1) DE69907166T2 (pt)
DK (1) DK1063230T3 (pt)
ES (1) ES2196772T3 (pt)
HU (1) HU225741B1 (pt)
ID (1) ID25589A (pt)
IL (1) IL138068A (pt)
MX (1) MXPA00008439A (pt)
NO (1) NO317882B1 (pt)
NZ (1) NZ506574A (pt)
PL (1) PL200666B1 (pt)
PT (1) PT1063230E (pt)
RU (1) RU2203887C2 (pt)
TR (1) TR200002505T2 (pt)
WO (1) WO1999043648A1 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1910151A (zh) * 2003-11-28 2007-02-07 三共株式会社 具有杂芳基环的环胺衍生物
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006002350A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN101233108A (zh) * 2005-05-27 2008-07-30 第一三共株式会社 具有取代烷基的环胺衍生物
RU2312660C2 (ru) * 2005-07-25 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО ПГФА Росздрава) 4-ацетил-3-гидрокси-1-(2-гидроксиэтиламиноэтил)-5-фенил-3-пирролин-2-он, проявляющий антикоагулянтную активность
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168022A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
SG11201505283RA (en) * 2013-01-09 2015-08-28 Univ Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
MX371538B (es) * 2015-04-30 2020-01-30 Univ Michigan Regents Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.
CN106554369A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554302A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
KR102903740B1 (ko) 2018-01-31 2025-12-24 더 리젠츠 오브 더 유니버시티 오브 미시간 티에노피리딘 화합물의 혼합된 이황화물 접합체를 합성하기 위한 생체촉매 및 방법
US11642335B2 (en) * 2019-09-26 2023-05-09 Board Of Regents, The University Of Texas System Chemical synthesis of clopidogrel active metabolites and disulfide conjugate prodrugs
CN111484446A (zh) * 2020-04-02 2020-08-04 北京翼方生物科技有限责任公司 氯吡格雷代谢活性体二硫衍生物、其制备方法及医药用途
CN111848497A (zh) * 2020-07-28 2020-10-30 内蒙古医科大学 氯吡格雷活性代谢物衍生物、其前药及其制备方法与应用
CN112851570A (zh) * 2021-01-13 2021-05-28 北京沃邦医药科技有限公司 不饱和环胺半胱氨酸二硫衍生物制备方法及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555854A (en) * 1896-03-03 Brush-handle attachment
US3647796A (en) * 1968-12-23 1972-03-07 Parke Davis & Co Cyclicamino alkylaminothioacridine
FR2215948B1 (pt) 1973-02-01 1976-05-14 Centre Etd Ind Pharma
FR2495156A1 (fr) * 1980-11-28 1982-06-04 Sanofi Sa Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
US4845121A (en) * 1986-06-13 1989-07-04 The Ohio State University Research Foundation Aci-reductone compounds belonging to the 6,7-disubstituted-3,4-dihydro benzopyan-2H-one class having antiaggregatory properties
JPH04334358A (ja) * 1991-05-02 1992-11-20 Ono Pharmaceut Co Ltd 縮合ベンゼンオキシ酢酸誘導体
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
AU3351293A (en) * 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1994022440A1 (en) * 1993-03-29 1994-10-13 Smithkline Beecham Corporation Bicyclic compounds which inhibit platelet aggregation
DK0621037T3 (da) 1993-04-23 2000-01-17 Hoechst Ag Pyridopyrimidindioner, fremgangsmåder til deres fremstilling samt deres anvendelse som lægemidler
EP1393723A3 (en) * 1993-09-17 2004-10-20 The Brigham And Women's Hospital, Inc. Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives

Also Published As

Publication number Publication date
CA2322171A1 (en) 1999-09-02
HUP0100950A2 (hu) 2001-08-28
US6610708B1 (en) 2003-08-26
HU225741B1 (en) 2007-07-30
AU737303B2 (en) 2001-08-16
BRPI9908319B1 (pt) 2012-01-10
EP1063230A1 (en) 2000-12-27
ATE238279T1 (de) 2003-05-15
KR20010041367A (ko) 2001-05-15
HUP0100950A3 (en) 2002-12-28
NO317882B1 (no) 2004-12-27
NO20004279D0 (no) 2000-08-25
ES2196772T3 (es) 2003-12-16
PT1063230E (pt) 2003-07-31
CZ300821B6 (cs) 2009-08-19
ID25589A (id) 2000-10-19
IL138068A (en) 2005-11-20
CN100369896C (zh) 2008-02-20
RU2203887C2 (ru) 2003-05-10
DE69907166T2 (de) 2004-02-05
CZ20003119A3 (cs) 2001-01-17
TR200002505T2 (tr) 2000-12-21
EP1063230A4 (en) 2001-12-12
WO1999043648A1 (en) 1999-09-02
PL200666B1 (pl) 2009-01-30
NO20004279L (no) 2000-10-26
MXPA00008439A (es) 2002-04-24
DE69907166D1 (de) 2003-05-28
CN1298389A (zh) 2001-06-06
IL138068A0 (en) 2001-10-31
DK1063230T3 (da) 2003-07-14
PL342573A1 (en) 2001-06-18
NZ506574A (en) 2003-06-30
AU2641399A (en) 1999-09-15
CA2322171C (en) 2009-10-27
KR100567950B1 (ko) 2006-04-05
BRPI9908319B8 (pt) 2021-07-06
EP1063230B1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
BRPI9908319A (pt) composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo.
BR9806413A (pt) Composto e uso do mesmo
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
BR9813848A (pt) Composto heterocìclico fundido substituìdo, uso do mesmo, e, composição farmacêutica.
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
FI980341A0 (fi) 2-oksi-indolijohdannaisia
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
FR2805817B1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
ATE223378T1 (de) Prolineamid-derivate
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
ATE104971T1 (de) 2-aminopyrimidinon-derivate.
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
BR0012697A (pt) Inibidores da diferenciação de th2
BR0010520A (pt) Novos compostos farmaceuticamente ativos
ES2120728T3 (es) Inhibidores de la agregacion de plaquetas.
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
BR9909253A (pt) Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
BR0110211A (pt) Derivados de oxadiazol tendo efeitos anticâncer
ES2123546T3 (es) Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras.
ES2110115T3 (es) Inhibidores de la agregacion de plaquetas.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/01/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 26.02.2019